Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(08): 497-502
DOI: 10.1590/0004-282X20170091
ARTICLES

Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages

Qualidade de vida de indivíduos com doença de Parkinson: marcadores da progressão da fase leve para moderada
Raissa Carla Moreira
1   Universidade Federal do Paraná, Curitiba PR, Brasil;
,
Marise Bueno Zonta
2   Universidade Federal do Paraná, Hospital de Clínicas, Departamento de Reabilitação, Curitiba PR, Brasil;
,
Ana Paula Serra de Araújo
3   Secretaria Municipal de Saúde, Prefeitura Municipal de Guarapuava, Guarapuava PR, Brasil;
,
Vera Lúcia Israel
4   Universidade Federal do Paraná, Departamento de Fisioterapia, Curitiba PR, Brasil;
,
Hélio A. G. Teive
5   Universidade Federal do Paraná, Departamento de Medicina, Curitiba PR, Brasil.
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Objective

To investigate which factors are associated with the quality of life decline in Parkinson’s disease patients from mild to moderate stages.

Methods

The Unified Parkinson’s Disease Rating Scale and Parkinson’s Disease Questionnaire-39 were used to evaluate clinical/functional data and the quality of life.

Results

The markers of clinical/functional worsening were drooling (p < 0.004), need for assistance with hygiene (p = 0.02), greater freezing frequency (p = 0.042), bradykinesia (p = 0.031), greater intensity of the resting tremor (p = 0.035) and “pill rolling” (p = 0.001). The decline in quality of life was related to stigma (p = 0.043), greater impairment in cognition (p = 0.002), mobility (p = 0.013) and for daily living activities (p = 0.05), and was considered more significant in men, married, older individuals, and those with a longer time of disease.

Conclusions

The quality of life worsening markers at the moderate stage were related to stigma, worsening of cognition, and to greater impairment in mobility and daily living activities.

RESUMO

Objetivo

Verificar os fatores relacionados ao declínio clínico/funcional e de Qualidade de Vida de indivíduos com Doença de Parkinson, da fase leve para moderada.

Métodos

Foram utilizadas as escalas Unified Parkinson’s Disease Rating Scale and Parkinson’s Disease Questionnaire-39 (UPDRS e PDQ-39) para avaliação clínico/funcional e de qualidade de vida

Resultados

Os marcadores de piora clínico/funcional na fase moderada foram: sialorréia (p < 0,004), necessidade de ajuda para higiene (p = 0,02), maior frequência do “freezing” (p = 0,042), bradicinesia (p = 0,031) e maior intensidade do tremor de repouso (p = 0,035) e bater dos dedos (p = 0,001). O declínio da qualidade de vida esteve relacionado ao estigma (p = 0,043), ao maior comprometimento da cognição (p = 0,002), da mobilidade (p = 0,013) e da independência para realizar as atividade de vida diária (AVD’s) (p = 0,05), sendo mais importante nos homens, nos casados, nos indivíduos com maior idade e naqueles com maior tempo de evolução da doença.

Conclusão

Os marcadores de piora da qualidade de vida na fase moderada estiveram relacionados ao estigma, à piora da cognição, ao maior comprometimento para mobilidade e AVD’s.

Parkinson disease - quality of life - surveys and questionnaires
doença de Parkinson - qualidade de vida - inquéritos e questionários


Publication History

Received: 25 November 2016

Accepted: 11 May 2017

Article published online:
05 September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson’s disease. Mov Disord. 2015;30(11):1442-50. https://doi.org/10.1002/mds.26354
  • 2 Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-601. https://doi.org/10.1002/mds.26424
  • 3 Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373(9680):2055-66. https://doi.org/10.1016/S0140-6736(09)60492-X
  • 4 Souza A, Barreto MM, Santos SMS. [Evaluation of functional activity and quality of life in women with Parkinson’s disease]. Saúde Pesqui. 2010;3(2):167-72. Portuguese.
  • 5 Ferreira FD, Ferreira FMD, Heleno RB, Mella-Júnior SE. [Parkinson’s disease: physiopathologic and therapeutic aspects]. Saúde Pesqui. 2010;3(2):221-8. Portuguese
  • 6 Silva PFC, Pereira RPR, Silva SM, Corrêa JCF, Corrêa FI. [Correlation between clinical profile, quality of life and disability of the patients of Associação Brasil Parkinson]. ConScientiae Saúde. 2010;10(4):650-6. Portuguese. https://doi.org/10.5585/conssaude.v10i4.3095
  • 7 Martinez-Martín P, Damián J. Parkinson’s disease: depression and anxiety in Parkinson’s disease. Nat Rev Neurol. 2010;6:243-5. https://doi.org/10.1038/nrneurol.2010.49
  • 8 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality Neurology. 1967;17(5):427-42. https://doi.org/10.1212/WNL.17.5.427
  • 9 Navarro-Peternella FM, Marcon SS. Quality of life of a person with Parkinson’s disease and the relationship between the time of evolution and the severity of the disease. Rev Lat Am Enfermagem. 2012;20(2):384-91. https://doi.org/10.1590/S0104-11692012000200023
  • 10 Fahn S, Elton R. Members of the UPDRS. Development Committee. The unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson’s disease. New York: McMellam Health Care Information; 1987. p.153-63.
  • 11 Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4(3),241-8. https://doi.org/10.1007/BF02260863
  • 12 Borges AEA, Mendes LM, Lemos MTM. [Physiotherapeutic perception of parkinsonian individuals correlating assessment scales]. Rev Bras Ci Saúde. 2014;18(3):187-94. Portuguese. https://doi.org/10.4034/RBCS.2014.18.03.01
  • 13 Pinheiro IM, Santos LLS, Paula LCN, Costa ACN. [Impact of Parkinson’s Disease in functionality and quality of life of elderly in a geriatric unit reference in the city of Salvador – Bahia]. Rev Ciênc Méd Biol. 2014;13(3):292-7. Portuguese. https://doi.org/10.9771/cmbio.v13i3.12933
  • 14 Navarro-Peternella FM, Marcon SS. [Living with Parkinson’s disease from the perspective of parkinsonians and their relatives]. Rev Gaúcha Enferm. 2010;31(3):415-22. Portuguese. https://doi.org/10.1590/S1983-14472010000300002
  • 15 Soares GS, Peyré-Tartaruga LA. [Parkinson’s disease and physical exercise: a literature review]. Cien Movimento. 2011;12(24):69-85. Portuguese. https://doi.org/10.15602/1983-9480/cmbs.v12n24p69-85
  • 16 Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80(3):276-81. https://doi.org/10.1212/WNL.0b013e31827deb74
  • 17 Massano J. [Parkinson’s disease: a clinical update]. Acta Med Port. 2011;24(84):827-34. Portuguese.
  • 18 Souza CF, Almeida HC, Sousa JB, Costa PH, Silveira YSS, Bezerra JC. [Parkinson’s disease and the process of aging motor: literature review]. Rev Neurocienc. 2011;19(4):718-23. Portuguese.
  • 19 Santos ISC, Menezes MR, Souza AS. [Elderly people’s conceptions of living with Parkinson’s disease]. Rev Enferm UERJ. 2009;17(1):69-74. Portuguese.
  • 20 Correia MGS, Paixão AO, Jesus AVF, Silva FS, Messias GMS, Nunes TGM et al. Doença de Parkinson: uma desordem neurodegenerativa. Cad Grad Ciênc Biol Saúde. 2013;1(16):57-65.
  • 21 Quintella RS, Sachetti A, Wibelinger LM, Oliveira SG. Qualidade de vida e funcionalidade na doença de Parkinson. RBCEH. 2013;10(1):104-12. https://doi.org/10.5335/rbceh.2012.1823
  • 22 Mandira ALS. [Study of positive influence on quality of life patients with Parkinson’s Disease participants Group Lotus]. Kairós Gerontol. 2012;15(4):185-99. Portuguese.
  • 23 Tavares DMS, Dias FA, Santos NMF, Haas VJ, Miranzi SC. Factors associated with the quality of life of elderly men. Rev Esc Enferm USP. 2013;47(3):678-85. https://doi.org/10.1590/S0080-623420130000300022
  • 24 Vara AC, Medeiros R, Striebel VLW. [Physical therapy in Parkinson’s disease]. Rev Neurocienc. 2012;20(2):266-72. Portuguese.
  • 25 Werle WR, Takeda SYM, Zonta MB, Guimarães ATB, Teive HAG. The physical, social and emotional aspects are the most affected in the quality of life of the patients with cervical dystonia. Arq Neuropsiquiatr. 2014;72(6):405-10. https://doi.org/10.1590/0004-282X20140044
  • 26 Rodríguez-Violante M, Cervantes-Arriaga, A, Corona T, Martínez-Ramírez D, Morales-Briceño H, Martínez-Martín P. Clinical determinants of health-related quality of life in Mexican patients with Parkinson’s disease. Arch Med Res. 2013;44(2):110-4. https://doi.org/10.1016/j.arcmed.2013.01.005
  • 27 Cetolin SF, Trzcinski C, Mahl AC, Steffani JÁ, Luccas TN, Presta AA. Alterações Sociofamiliares na vida de pessoa com mal de Parkinson usuárias da saúde pública. UNOESC Ciência – ACHS. 2012;3(2):203-12.
  • 28 Tedrus GMAS, Fonseca LC, Kange PM. Parkinson’s diseasei of clinical and cognitive aspects on quality of life. Dement Neuropsychol. 2010;4(2):131-7. https://doi.org/10.1590/S1980-57642010DN40200010
  • 29 Filippin NT, Martins JS, Libera LBD, Halberstadt BF, Severo AR. [Quality of life of subjects with Parkinson’s disease and caregivers]. Fisioter Mov. 2014;27(1):57-66. Portuguese. https://doi.org/10.1590/0103-5150.027.001.AO06